aur106

AUR106 is an orally bioavailable small molecule inhibitor that targets both TIGIT (T-cell immunoreceptor with immunoglobulin and ITIM domains) and PD-L1 (programmed death-ligand 1), two key immune checkpoint proteins involved in tumor immune evasion. By simultaneously inhibiting TIGIT and PD-L1, AUR106 aims to enhance anti-tumor immune responses by blocking inhibitory signals that suppress T-cell activity. Developed from Aurigene's small molecule immuno-oncology platform, AUR106 offers potential advantages over antibody-based therapies, such as oral administration, ease of combination dosing, improved management of immune-related adverse events, and lower cost of goods. The drug is currently in Phase 1 clinical trials for various advanced solid tumors including non-small cell lung cancer, gastric cancer, urothelial cancer (including advanced urothelial carcinoma), kidney cancer, colon cancer, esophageal cancer, gastrointestinal cancers, colorectal cancer and transitional cell carcinoma.